RBC Capital Initiates Coverage On Fusion Pharmaceuticals with Outperform Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has initiated coverage on Fusion Pharmaceuticals (NASDAQ:FUSN) with an Outperform rating and set a price target of $12.

December 20, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has initiated coverage on Fusion Pharmaceuticals with an Outperform rating and a price target of $12.
The initiation of coverage by RBC Capital with an Outperform rating typically indicates a positive outlook on the stock, suggesting that the analyst believes the stock will perform better than the broader market. The announcement of a price target of $12, which is likely above the current trading price, suggests a significant upside potential. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100